Table 3. Medical therapies initiated on RA patients that participated in the microarray studies.
| Dataset | Patients | Medical Therapies |
|---|---|---|
| GSE7307 | All the patients were not treated | |
| GSE12021A | RA1 | NSARD + Azulfidine + Prednisolone |
| RA2 | NSARD + MTX + Prednisolone | |
| RA3 | NSARD + MTX+ Prednisolone | |
| RA4 | NSARD + Azulfidine + Prednisolone + MTX | |
| RA5 | NSARD + MTX + Prednisolone | |
| RA6 | NSARD + Azulfidine + Prednisolone | |
| RA7 | MTX + Prednisolone | |
| RA8 | NSARD | |
| RA9 | NSARD + Prednisolone | |
| RA10 | NSARD + Prednisolone | |
| RA11 | COX-2 inhibitor + Prednisolone + Quensyl | |
| RA12 | NSAID + Tilidin + Prednisolone | |
| GSE12021B | RA1 | NSARD + Azulfidine + Prednisolone |
| RA2 | NSARD + MTX + Prednisolone | |
| RA3 | NSARD + MTX+ Prednisolone | |
| RA4 | NSARD + Azulfidine + Prednisolone + MTX | |
| RA5 | NSARD + MTX + Prednisolone | |
| RA6 | NSARD + Azulfidine + Prednisolone | |
| RA7 | MTX + Prednisolone | |
| RA8 | NSARD | |
| RA9 | NSARD + Prednisolone | |
| RA10 | NSARD + Prednisolone | |
| RA11 | COX-2 inhibitor + Prednisolone + Quensyl | |
| RA12 | NSAID + Tilidin + Prednisolone | |
| GSE55457 | RA1 | NSARD + Azulfidine + Prednisolone |
| RA2 | NSARD + MTX + Prednisolone | |
| RA3 | NSARD + MTX+ Prednisolone | |
| RA4 | NSARD + Azulfidine + Prednisolone + MTX | |
| RA5 | NSARD + MTX + Prednisolone | |
| RA6 | NSARD + Azulfidine + Prednisolone | |
| RA7 | MTX + Prednisolone | |
| RA8 | NSARD | |
| RA9 | NSARD + Prednisolone | |
| RA10 | no therapy used | |
| RA11 | NSARD + Prednisolone | |
| RA12 | COX-2 inhibitor + Prednisolone + Quensyl | |
| RA13 | NSAID + Tilidin + Prednisolone | |
| GSE55235 | Therapies not mentioned for these two datasets | |
| GSE77298 |
NSARD, nonsteroidal anti-rheumatic drug; MTX, methotrexate; COX-2, cyclooxygenase-2; NSAID, nonsteroidal anti-inflammatory drug